Fortress Biotech, Inc. (FBIOP) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
Analysts estimate Earnings Per Share (EPS) of $-3.51 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.69 vs est $-3.51 (beat +23.3%). 2025: actual $-0.07 vs est $0.32 (missed -122.2%). Analyst accuracy: 0%.
FBIOP Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Fortress Biotech, Inc. in the past 3 months
EPS Estimates — FBIOP
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.69
vs Est –$3.51
▲ 30.4% off
2025
Actual –$0.07
vs Est $0.32
▼ 550.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — FBIOP
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.058B
vs Est $0.057B
▲ 0.9% off
2025
Actual $0.061B
vs Est $0.073B
▼ 19.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
